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Abstract 
The growing incidence of opiate addiction in the United States has been declared a public health 
emergency (Hargan, 2017).  Vivitrol, a monthly injectable extended-release naltrexone, helps to 
block the cravings of opiates so patients can focus on changing their behavior and lifestyle.  
Counseling has been suggested as an effective adjunctive therapy when used concurrently with 
Vivitrol.  This study is a retrospective chart review and aims to compare the outcomes between 
two groups of patients; one that receives the monthly Vivitrol injection plus attend regular 
counseling and one group, equal in size, that receives Vivitrol alone. 
Keywords: Vivitrol, opiate-addiction, recovery success, counseling, self-efficacy, 
research 
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Recovery Success Through Combined Use of Vivitrol and Counseling versus Pharmacological 
Treatment Alone in Opiate-Addicted Patients 
 The growing incidence of opiate addiction in the United States has been declared a 
public health emergency (Hargan, 2017).  Opiate addicts come from every socioeconomic class 
and walk of life.  This project seeks to compare the outcomes in recovery success for persons 
receiving naltrexone as a medication assisted treatment (MAT) and persons receiving both 
naltrexone and counseling concurrently. 
Background 
Drug and alcohol abuse are a growing concern worldwide and have many negative 
consequences on the health and well-being of those affected (Bashirian, Hidarnia, 
Allahverdipour, & Hajuzadeh, 2012).  Tennessee ranks higher than the national average for 
opioid-overdose deaths at 19.3 per 100,000 persons compared to 14.6 per 100,000 persons, 
according to 2017 data (National Institute on Drug Abuse, 2019). Tennessee ranked third 
nationally for highest number of opioid prescriptions, with 94.4 prescriptions for every 100 
persons.  The Tennessee Department of Health requires that all Neonatal Abstinence Syndrome 
(NAS) cases be reported within 30 days of birth and in 2017 there were over 1,000 cases, 
representing 1.35% of all live births. Of the NAS cases reported, nearly 1 in 3 were as a result of 
diverted opioid medications (National Institute on Drug Abuse, 2019).  Addiction is defined as, 
“an inability to consistently abstain, impairment in behavioral control, craving, diminished 
recognition of significant problems with one’s behaviors and interpersonal relationships, and a 
dysfunctional emotional response” (ASAM, 2011).  The problem of addiction has been studied 
by numerous investigators in efforts to determine factors contributing to recovery success. 
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Problem Statement 
Opioid dependence has been linked with increased rates of morbidity and mortality, 
increased healthcare costs, and psychological suffering for the addict and their family. 
Substances used in opioid dependence can be illicit, like heroin, or illicitly acquired or misused 
prescription medications, such as morphine, hydrocodone, oxycodone, and buprenorphine  
(Kjome & Moeller, 2011).  The Food and Drug Administration (FDA) approved extended-
release naltrexone (Vivitrol) for treatment of alcohol dependence in 2006 and to prevent opioid 
relapse in 2010.  Vivitrol is an intramuscular injectable opioid antagonist released over 28 days 
used to block the cravings of opiates (Alanis-Hirsch, et al., 2015).  The FDA approval of this 
medication allowed providers to have an alternative treatment to agonist therapy, such as 
methadone and buprenorphine, which carry the risk of diversion and abuse.  Naltrexone does not 
cause the development of dependence or tolerance over time, and dosing cessation does not 
result in withdrawal (Kjome & Moeller, 2011). 
It has been advised to combine medications with counseling for better recovery success 
outcomes but there is limited data available in the literature of studies on Vivitrol and 
counseling. Many of the studies focus on the effects of Buprenorphine as the primary medication 
assisted treatment (MAT). In a systematic review by Dugosh et al. of the current treatment 
options available for addiction, a significant gap was noted and a suggested a need for future 
research. Due to the enormity of the nation’s current opioid epidemic, it is critical that health 
care providers learn the most effective ways to treat addiction (Dugosh, et al., 2016). This study 
aims to determine if psychosocial interventions are an essential part of addiction treatment, when 
combined with the medication Vivitrol. 
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Clinical Question 
Opioid abuse can be a lifelong battle that requires substantial resources and therapeutic 
efforts by the patient, families, and health care providers (Taylor, Raffa, & Pergolizzi, 2011).  
The purpose of this project is to compare outcomes between recovery success variables for 
persons receiving Vivitrol and persons receiving Vivitrol and counseling concurrently.  The 
population of interest in this project is patients suffering from opiate addiction.  The 
interventions being compared are Vivitrol alone versus Vivitrol plus counseling.  Counseling 
will be defined as a monthly counseling session (either group or individual therapy) by a licensed 
addiction counselor or social worker.  The goal of this project is to determine if combined 
therapy of Vivitrol and counseling is superior to Vivitrol alone in this sample population. This 
comparison study will determine if there is evidence of a greater likelihood of recovery success 
within the sample population that can support the efficacy of Vivitrol alone or Vivitrol in 
addition to counseling. 
Significance 
The rate of both illicit and prescription drug abuse has steadily risen throughout the 
United States. Meanwhile, the efforts by health care providers to offer better treatments for pain 
have consequently caused a rise in misuse, abuse, addiction, and diversion of many prescription 
opioids (Taylor, Raffa, & Pergolizzi, 2011).  Some have even called the current epidemic the 
worst in the history of the United States, with an estimated 92 million American adults reporting 
the abuse or misuse of prescription opioids in 2015.  From a financial standpoint, it has been 
estimated that the opioid epidemic costs the United States approximately $78 billion annually 
(Stuart, et al., 2018). According to the World Health Organization (WHO), investing in 
evidence-based treatment for substance abuse decreases negative health outcomes and social 
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effects such as crime, economic burden, and Hepatitis C and HIV infections. For every dollar 
spent on addiction treatment, seven dollars are return in cost-savings (World Health 
Organization, 2019). 
Opioid addiction is difficult to treat because it is a chronic, relapsing condition that 
requires substantial effort in treatment plan development using a collaborative approach for best 
success (Stuart, et al., 2018).  Evaluating the recovery success for these treatments will assist in 
building evidence-based recommendations in the treatment of persons with opiate addiction. This 
project will add to the existing body of nursing knowledge in opiate-addiction treatment.   
Review of Literature 
Vivitrol Success 
In a 24-week randomized controlled trial comparing Vivitrol to placebo in individuals 
with current opioid dependence, subjects completed a 30-day detoxification and received either 
the 380mg Vivitrol injection or placebo injection every 4 weeks. Data was collected based on 
urine drug screens and self-report of relapse and craving control. Opioid-free weeks were 
significantly different between treatment groups with a median of 90% of opioid-free urine 
screens in the Vivitrol group and only 35% in the placebo group. Subjects in the Vivitrol group 
reported a 50% mean reduction in subjective craving compared with no change in craving for 
subjects receiving placebo.  Retention rates in the 24-week program were significantly longer in 
the subjects receiving Vivitrol compared to the placebo group (Kjome & Moeller, 2011). 
Combination of Drug and Psychosocial Support 
Dunn et al. (2013) examined psychosocial interventions delivered in conjunction with 
Vivitrol to treat opiate addiction. Subjects were divided into two groups: individuals receiving 
therapeutic counseling in addition to Vivitrol and individuals receiving therapeutic counseling 
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alone. Findings indicated that the participants receiving both counseling and Vivitrol as opposed 
to counseling alone had a higher percentage of subjects who completed the entire 6 months of 
injectable naltrexone. However, there were no differences in relapse into opiate use, verified by 
urine drug screens, between the two groups (Dugosh, et al., 2016). 
 Another study evaluated the subjects receiving psychosocial plus maintenance 
pharmacological treatment (Vivitrol) and standard maintenance treatment alone.  Neither group 
reported any difference in depression or psychiatric symptoms, but the subjects in the combined 
Vivitrol and therapy group showed a higher rate of abstinence at the end of the program. In 
addition, the combined medication plus therapy was shown to be more likely to produce positive 
effects in retention of maintaining abstinence (Taylor, Raffa, & Pergolizzi, 2011). 
Theoretical Framework. 
The theoretical model that guides this project is the Transtheoretical Model of Behavioral 
Change.  This model describes how long-term behavior changes such as remaining abstinent, 
surrounding oneself with positive influences, and leading a productive lifestyle, involve multiple 
actions and adaptations over time. The stages of change include precontemplation (no 
recognition of need for change), contemplation (thinking about change), preparation (planning 
for change), action (adopting new habits), and maintenance (ongoing practice of new behavior or 
healthier lifestyle) (Butts & Rich, 2018).   
This model helps explain how co-morbid conditions can affect an individual’s thought 
processes.  Individuals with comorbid conditions, such as mental or substance-abuse disorders, 
rely on different processes as they learn new behaviors and may need different interventions than 
those without a mental health or substance-abuse problem (Butts & Rich, 2018).  Patients 
suffering from addiction, especially, may not always move through stages in a linear pattern and 
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often repeat certain stages. For example, one can admit they have a problem with addiction and 
desire to change. They may change their phone number, move out of the environment they were 
living in, and remain abstinent for several months. Depending on their personal level of 
motivation and self-efficacy, it is easy for them to relapse and return to the earlier stages of 
change. Awareness of this model will inform and guide the investigators in data analysis.  
Project Design 
This project is a descriptive design utilizing a retrospective chart review comparing 
recovery success for persons receiving Vivitrol plus counseling versus Vivitrol alone.  
Inclusion and Exclusion Factors 
Inclusion criteria for this study include patient’s aged 18 and older, current opiate 
addiction, and consent to treat and receive Vivitrol injection. Exclusion criteria for this study 
include patients under the age of 18, a reported allergy to the Vivitrol injection, or refusal of 
consent to treat and receive the injection.   
Operational Definitions 
Successful recovery is defined as maintaining abstinence through report of appropriate 
urine drug screen and patient’s self-report of denial of opiate relapse.  Relapse is defined as an 
inappropriate or failed urine drug screen or patient’s self-report of opiate-relapse. Counseling is 
recommended on a monthly basis, but not required. Those patients who attend counseling are 
compared to those that choose not to attend. 
Setting 
Westbrook Medical Center is a family medicine office located in a mid-size city in the 
Appalachian region of the Southeastern United States. The office offers primary care and 
addiction treatment to patients of all ages. They have a successful Vivitrol program that is 
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recommended to last 12-18 months and is designed to incorporate both the monthly injection and 
counseling sessions with the onsite counselor.  
Method 
 This comparison study was conducted through a retrospective chart review of the patients 
at Westbrook Medical Center.   
Data Collection 
Data collection occurred over three months: May 15, 2019 to July 15, 2019. The total 
time abstinent for each patient varied since data was collected during a random point in the 
program, rather than start to finish. Some of the patients may have been in their first month of 
abstinence with only one Vivitrol injection thus far and some may have been 9-10 months free of 
opiate relapse.  The following variables were abstracted from the patient’s medical record: 
gender, age, insurance type (socioeconomic status), current opiate-addiction, number of months 
receiving Vivitrol, number of months abstinent of opiates, attendance of counseling, urine drug 
screen results, and patient self-report of cravings.  Westbrook uses an electronic medical record 
and all charts are password protected, ensuring secured data storage.  The data was collected on a 
Microsoft Excel spreadsheet without patient identifiers. The study is considered IRB exempt 
category 4 since it is conducted with existing data, documents, records, pathological specimens, 
and/or diagnostic specimens, and the information is recorded by the investigator so that the 
subjects cannot be identified. 
Counseling Attendance 
Counseling has been suggested as a critical intervention as adjunctive therapy with 
Vivitrol. Because counseling is recommended but not required in Westbrook’s program, it is an 
ideal location for a retrospective chart review to compare the group of patients that attend 
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counseling on a regular basis with the patients that do not attend counseling. The attendance of 
counseling is documented in every patient’s chart at each visit. This study aims to evaluate if 
counseling makes a difference in the outcome of recovery success.  
Sample Size 
The sample size was determined by matching the selected number of persons receiving 
Vivitrol and counseling to those receiving Vivitrol alone. During the planning and data collection 
period, it was decided that 25 patients in each group be evaluated, with a total of 50 patient 
charts for this project.   
Results 
Analysis 
The data was entered into a Microsoft Excel spreadsheet for analysis. The spreadsheets 
are secured by the investigator on a password-protected laptop to which only the investigator has 
access.  All data collected will be deleted from the laptop in December 2019 upon completion of 
this project and this program. 
Statistician Consult 
A statistician was consulted to conduct the appropriate statistical tests to determine the 
difference between the two groups in the sample.  Dr. Eric Heidel, a University of Tennessee 
statistician, conducted these tests and corresponded via email. The statistical test tables can be 
found at the end of this paper. 
Statistical Findings 
In the sample of 50 patient-charts reviewed, there were 25 subjects in the Vivitrol plus 
counseling group and 25 subjects in the Vivitrol alone group. There were 11 male and 39 female 
subjects overall. The Vivitrol alone group had 9 male and 16 female and the Vivitrol plus 
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counseling group had 2 male and 23 female subjects. 86% of these patients had either 
government insurance or were non-insured. The remaining 14% had commercial insurance. 
Statistical tests were computed based on the variables mentioned previously, such as age, 
number of months receiving Vivitrol, and number of months abstinent of opiates.  
As presented in the Appendix, these variables are used to compare the difference between 
the two groups in Table 1. In the Vivitrol alone group, the mean age was 33, mean number of 
months receiving Vivitrol was 5.2, and mean number of months abstinent of opiates was 6.2. In 
the Vivitrol plus counseling group, the mean age was 34, mean number of months receiving 
Vivitrol was 9.2 and mean number of months abstinent of opiates was 10.1.  There is a 
significant difference between the groups for number of months receiving Vivitrol and remaining 
abstinent of opiates. This indicates a greater likelihood of remaining abstinent of opiates the 
longer a patient is receiving the Vivitrol injection. 
Table 2, also located in the Appendix, presents the frequency and percentage statistics for 
Chi-Square. Gender, insurance, self-reported cravings, and UDS results were compared between 
the Vivitrol only and Vivitrol plus counseling groups in the sample size.  There is a significant 
difference in positive drug screens between the two groups.  Those receiving both Vivitrol and 
counseling had 21 subjects with negative (clean) UDS and 4 positive (failed) UDS. They were 
85.8% less likely to have a positive (failed) drug screen than the Vivitrol alone group that had 14 
negative (clean) and 11 positive (failed) screens.  There was also a significant difference between 
the treatment groups for gender. Women had 6.47 times higher odds of having both Vivitrol and 
counseling, representing 92% of that group.  There was a non-significant difference between the 
groups for insurance type or self-report of cravings. 
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Discussion 
Summary of Findings 
The goal for the study was to discover if combined therapy of Vivitrol plus counseling is 
superior to Vivitrol alone in recovery success. The hypothesis was that combined therapy would 
prove to be superior to medication therapy alone. This hypothesis was tested during this project. 
It has been advised to combine MAT with counseling for better recovery success outcomes but 
there is limited data available in the literature of studies on Vivitrol and counseling. After 
reviewing the findings of the statistical methods used, it is well supported by these results that 
Vivitrol combined with counseling is far better than pharmacological treatment alone. In this 
sample population, the patients with combined Vivitrol and counseling were 85.8% less likely to 
have a positive urine drug screen. This means that these patients remained abstinent while on the 
combined therapy. In contrast, the patients who received Vivitrol alone without counseling were 
only about 15% likely to have a negative (clean) urine drug screen. 
Implications for Future Nursing Practice 
It is also noted in the findings that women were about 6 times more likely to choose the 
Vivitrol plus counseling option. This means that out of the selected sample size, men were about 
6 times less likely to attend counseling while receiving Vivitrol. That is a very relevant finding.  
Differences in gender pertaining to addiction treatment was not one of the original research 
questions but could absolutely be a topic for future nursing research.  
Contrary to the findings in this study from a selected sample size, recent studies have 
indicated that men have actually been shown to be more likely to seek therapy than women 
(Becker, McClellan, & Reed, 2017). Due to the stigma associated with mental health issues in 
society, therapy can be a shameful experience to patients suffering from addiction. Individuals 
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dealing with issues in need of therapy may feel that they will be viewed as weak, flawed, or 
unable to handle everyday stressors if they seek help. Women are more shame prone than men 
due to social norms and are therefore less likely to seek psychosocial help (Miller-Prieve, 2016).  
Additionally, men experience less stigma than women pertaining to seeking help for addiction. 
When combined with less social support, that means an increased likelihood of isolation and 
greater risk of relapse for women than men (Becker, McClellan, & Reed, 2017). 
This study can be added to the existent body of nursing knowledge as evidence that 
combined therapy is significantly more effective in maintaining recovery success. During the 
literature review, many studies also indicated a greater likelihood of recovery success through 
combined use of MAT and psychosocial intervention, but few studies have been published on 
Vivitrol combined with counseling (Dugosh, et al., 2016). This study will aid in education for 
patients on the reason behind the recommendation to attend counseling and receive their monthly 
Vivitrol injection.  
Strengths and Limitations of the Study 
One of the strengths of this project is the ability to collect data from existing patients 
from Westbrook Medical Center.  There are enough patients in the sample size to have equal 
groups of patients receiving Vivitrol plus counseling as well as those receiving Vivitrol alone. As 
mentioned earlier, the study was performed at a random point in the program with patient’s total 
time receiving Vivitrol, counseling, and/or remaining abstinent varying and no prompting was 
given prior to the data collection. The retrospective review format of this project improves the 
strength and accuracy of the study. 
A weakness noted only after reviewing the results of the study would be the limited 
number of clinical questions for this project. If more questions were asked prior to data 
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collection and analysis, the results could have presented a broader picture of addiction treatment 
instead of only focusing on treatment method. Questions that could have been asked include: 
Does gender play a role in counseling attendance? Does age or socioeconomic status play a role 
in the notion of readiness to change and compliance in the Vivitrol program? Since counseling 
was recommended but not required in Westbrook’s program, does this indicate an increased level 
of motivation or self-efficacy in those individuals who chose to attend regular counseling 
sessions? These questions would have greatly extended the amount of research needed to 
complete the project but would have added to the impact. 
Conclusion 
The purpose of this project was to evaluate if Vivitrol combined with counseling was 
superior to Vivitrol alone in recovery success. The study was completed using a retrospective 
chart review at a clinic with an existing patient base who were attending monthly appointments. 
As a result of the significant findings in this project, research clearly supports that Vivitrol and 
counseling combined is far more likely to achieve recovery success as opposed to the medication 
alone. Knowledge of this information should serve as a call to action to providers on the 
importance of combination therapy for addiction treatment in their patients.  
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Appendix 
Table 1. 
Descriptive Statistics for Independent Samples t-tests 
Variable Vivitrol only Vivitrol and Counseling p-value 
Age 33.8 (9.3) 34.4 (8.5) 0.80 
Number of months receiving Vivitrol 5.2 (6.6) 9.2 (7.1) 0.045 
Number of months abstinent of opiate 6.2 (8.4) 10.1 (7.7) 0.09 
Note: Values are mean (standard deviation) 
 
Table 2. 
Frequency and Percentage Statistics for Chi-square 
Outcome Level Vivitrol Vivitrol and Counseling p-value 
Gender     
 Male 9 (36.0%) 2 (8.0%)  
 Female 16 (64.0%) 23 (92.0%) 0.017 
Insurance     
 BCBS 3 (12.0%) 4 (16.0%)  
 Medicaid 19 (76.0%) 21 (84.0%)  
 None 3 (12.0%) 0 (0.0%) 0.20 
Self-reported cravings     
 No 20 (80.0%) 22 (88.0%)  
 Yes 5 (20.0%) 3 (12.0%) 0.44 
UDS results     
 Negative 14 (56.0%) 21 (84.0%)  
 Positive 11 (44.0%) 4 (16.0%) 0.03 
Note: Values are Frequency (percentage) 
 
